PMID- 26554798
OWN - NLM
STAT- MEDLINE
DCOM- 20160218
LR  - 20181202
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 44
DP  - 2015 Nov
TI  - Renal Denervation: A Potential Novel Treatment for Type 2 Diabetes Mellitus?
PG  - e1932
LID - 10.1097/MD.0000000000001932 [doi]
LID - e1932
AB  - Type 2 diabetes mellitus (T2DM) is a group of metabolic diseases of multiple 
      etiologies. Although great progress has been made, researchers are still working 
      on the pathogenesis of T2DM and how to best use the treatments available. Aside 
      from several novel pharmacological approaches, catheter-based sympathetic renal 
      denervation (RDN) has gained a significant role in resistant hypertension, as 
      well as improvements in glycemic control in T2DM.In this article, we will 
      summarize herein the role sympathetic activation plays in the progression of T2DM 
      and review the recent clinical RDN experience in glucose metabolism.We performed 
      systematic review in online databases, including PubMed, EmBase, and Web of 
      Science, from inception until 2015.Studies were included if a statistical 
      relationship was investigated between RDN and T2DM.The quality of each included 
      study was assessed by Newcastle-Ottawa scale score. To synthesize these studies, 
      a random-effects model or a fixed-effects model was applied as appropriate. Then, 
      we calculated heterogeneity, performed sensitivity analysis, tested publication 
      bias, and did meta-regression analysis. Finally, we identified 4 eligible 
      articles.In most studies, RDN achieved via novel catheter-based approach using 
      radiofrequency energy has gained a significant role in resistant hypertension, as 
      well as improvements in glycemic control in T2DM. But the DREAMS-Study showed 
      that RDN did not change median insulin sensitivity nor systemic sympathetic 
      activity.Firstly, the current published studies lacked a proper control group, 
      along with the sample capacity was small. Also, data obtained in the subgroups of 
      diabetic patients were not separately analyzed and the follow-up period was very 
      short. In addition, a reduction in blood pressure accounts for the improvements 
      in glucose metabolism and insulin resistance cannot be excluded.If the favorable 
      result of better glucose metabolism is confirmed in large-scale, randomized 
      studies, RDN may emerge as a novel therapeutic option for patients with T2DM.
FAU - Pan, Tao
AU  - Pan T
AD  - From the Department of Interventional and Vascular Surgery, Zhongda Hospital, 
      Southeast University, Jiangsu, China.
FAU - Guo, Jin-he
AU  - Guo JH
FAU - Teng, Gao-jun
AU  - Teng GJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Diabetes Mellitus, Type 2/*surgery
MH  - Humans
MH  - Kidney/*innervation
MH  - Sympathectomy/*methods
PMC - PMC4915899
COIS- The authors declare that they have no competing interests.
EDAT- 2015/11/12 06:00
MHDA- 2016/02/19 06:00
PMCR- 2015/11/06
CRDT- 2015/11/12 06:00
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2016/02/19 06:00 [medline]
PHST- 2015/11/06 00:00 [pmc-release]
AID - 00005792-201511030-00038 [pii]
AID - 10.1097/MD.0000000000001932 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Nov;94(44):e1932. doi: 10.1097/MD.0000000000001932.